TY - JOUR
T1 - Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma
T2 - the phase II GATHER study
AU - Sharman, Jeff P.
AU - Forero-Torres, Andres
AU - Costa, Luciano J.
AU - Flinn, Ian W.
AU - Inhorn, Lowell
AU - Kelly, Kevin
AU - Bessudo, Alberto
AU - Fayad, Luis E.
AU - Kaminski, Mark S.
AU - Evens, Andrew M.
AU - Flowers, Christopher R.
AU - Sahin, Deniz
AU - Mundt, Kirsten E.
AU - Sandmann, Thomas
AU - Fingerle-Rowson, Günter
AU - Vignal, Charlotte
AU - Mobasher, Mehrdad
AU - Zelenetz, Andrew D.
N1 - Publisher Copyright:
© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/3/21
Y1 - 2019/3/21
N2 - This study investigated the safety and efficacy of obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) in patients with advanced diffuse large B-cell lymphoma (DLBCL) and explored the impact of cell-of-origin (COO) on patient outcomes. Patients (N = 100) received obinutuzumab (1000 mg on the days 1, 8, and 15 of cycle 1, and day 1 of cycles 2–8) plus CHOP (cycles 1–6). For patients without grade ≥3 infusion-related reactions (IRRs) to standard-rate obinutuzumab infusion, a shorter duration of infusion (SDI) was evaluated. Overall and complete response rates, as determined according to the Cheson et al. criteria by investigators/independent radiological facility, were 82.0/75.0% and 55.0/58.0%, respectively. SDI of 120 minutes and 90 minutes were well tolerated with no grade ≥3 IRRs. Among all patients, IRRs typically occurred during cycle 1, day 1. G-CHOP is active and has an acceptable safety profile in the first-line treatment of patients with advanced DLBCL. Clinical Trials: NCT01414855DLBCL.
AB - This study investigated the safety and efficacy of obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) in patients with advanced diffuse large B-cell lymphoma (DLBCL) and explored the impact of cell-of-origin (COO) on patient outcomes. Patients (N = 100) received obinutuzumab (1000 mg on the days 1, 8, and 15 of cycle 1, and day 1 of cycles 2–8) plus CHOP (cycles 1–6). For patients without grade ≥3 infusion-related reactions (IRRs) to standard-rate obinutuzumab infusion, a shorter duration of infusion (SDI) was evaluated. Overall and complete response rates, as determined according to the Cheson et al. criteria by investigators/independent radiological facility, were 82.0/75.0% and 55.0/58.0%, respectively. SDI of 120 minutes and 90 minutes were well tolerated with no grade ≥3 IRRs. Among all patients, IRRs typically occurred during cycle 1, day 1. G-CHOP is active and has an acceptable safety profile in the first-line treatment of patients with advanced DLBCL. Clinical Trials: NCT01414855DLBCL.
KW - Efficacy
KW - obinutuzumab
KW - safety profile
UR - http://www.scopus.com/inward/record.url?scp=85054349595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054349595&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1515940
DO - 10.1080/10428194.2018.1515940
M3 - Article
C2 - 30277102
AN - SCOPUS:85054349595
SN - 1042-8194
VL - 60
SP - 894
EP - 903
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -